Spermosens AB (SPERM.ST)
SEK 0.01
(-3.23%)
SEK 0.01
(-3.23%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -169 Thousand SEK | -123.34% |
| 2022 | 724 Thousand SEK | -80.03% |
| 2021 | 3.62 Million SEK | 346.98% |
| 2020 | 811 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -45 Thousand SEK | 0.0% |
| 2024 Q2 | -45 Thousand SEK | 0.0% |
| 2024 Q3 | -44 Thousand SEK | 2.22% |
| 2023 FY | -169 Thousand SEK | -123.34% |
| 2023 Q4 | -45 Thousand SEK | -4.65% |
| 2023 Q2 | -42 Thousand SEK | -5.0% |
| 2023 Q1 | -40 Thousand SEK | -111.56% |
| 2023 Q3 | -43 Thousand SEK | -2.38% |
| 2022 Q4 | 346 Thousand SEK | 62.44% |
| 2022 Q3 | 213 Thousand SEK | 198.61% |
| 2022 Q2 | -216 Thousand SEK | -156.69% |
| 2022 Q1 | 381 Thousand SEK | -74.55% |
| 2022 FY | 724 Thousand SEK | -80.03% |
| 2021 Q1 | -32 Thousand SEK | -108.1% |
| 2021 Q4 | 1.49 Million SEK | 18.06% |
| 2021 FY | 3.62 Million SEK | 346.98% |
| 2021 Q3 | 1.26 Million SEK | 42.47% |
| 2021 Q2 | 890 Thousand SEK | 2881.25% |
| 2020 Q3 | 71 Thousand SEK | -58.72% |
| 2020 FY | 811 Thousand SEK | 0.0% |
| 2020 Q2 | 172 Thousand SEK | 0.0% |
| 2020 Q4 | 395 Thousand SEK | 456.34% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AroCell AB (publ) | -2.1 Million SEK | 91.96% |
| Devyser Diagnostics AB (publ) | 148.1 Million SEK | 100.114% |
| Immunovia AB (publ) | -5.1 Million SEK | 96.691% |
| Prostatype Genomics AB (publ) | -18.09 Million SEK | 99.066% |
| SenzaGen AB | 34.93 Million SEK | 100.484% |